Trump signs executive order imposing 100% tariff on some imported pharmaceutical drugs
The order targets certain pharma imports, escalating trade pressure on drugmakers with global supply chains.
Supply Chain Dive · +13 outlets
Pfizer to halt development of closely watched weight-loss drug
The move removes a would-be entrant from the obesity drug race dominated by Novo Nordisk and Eli Lilly.
www.polskieradio.pl · +5 outlets
Trump announces deals to cut weight-loss drug prices
The pricing deal is projected to save $64.3B over 10 years, part of broader GLP-1 cost negotiations.
Meteo.gr · +14 outlets
India's NPPA caps trade margins on 137 anti-cancer drugs at 30%, prices to fall from Nov 9
The margin cap is expected to cut retail prices of the cancer drugs by up to 70% and has drawn mixed industry reaction.
The Economic Times · +14 outlets
Novo Nordisk cuts price of Wegovy in China as weight-loss drug price war intensifies
Falling prices in major markets signal intensifying competition among obesity drugmakers.
Meteo.gr · +13 outlets
Canada authorizes first generic weight-loss drug, impacting pharmaceutical stocks
The first generic GLP-1 approval in Canada pressures branded obesity drug pricing.
www.polskieradio.pl · +4 outlets
ImmunityBio's Anktiva wins FDA expanded approval for broader bladder cancer use
The early approval broadens Anktiva's label ahead of the FDA deadline, boosting the company's flagship cancer therapy.
Simply Wall Street · +12 outlets
FDA approves Tudriqev for advanced refractory melanoma
The approval adds a new option for patients with difficult-to-treat advanced melanoma.
scanx.trade · +10 outlets
Compass Pathways' psilocybin therapy hits primary endpoint in Phase 3 treatment-resistant depression trial
A positive late-stage readout for a psychedelic-based therapy would be a milestone for the sector.
Stocktwits · +9 outlets
Intellia surges ahead of first-ever Phase 3 readout for gene-editing therapy
The upcoming readout would be the first Phase 3 data for a CRISPR-based gene-editing therapy.
Stocktwits · +2 outlets
Gilead Sciences rides FDA approval hot streak, drawing investor attention
A run of regulatory wins has raised questions about whether Gilead's stock still offers upside.
The Motley Fool · +2 outlets
Capricor and investors brace for FDA panel on Duchenne cell therapy deramiocel
A pivotal FDA advisory panel decision looms for the Duchenne muscular dystrophy cell therapy.
Stocktwits · +3 outlets
Big Pharma chases China biotech as obesity drug deals surge
Licensing activity for Chinese obesity assets accelerates as multinationals seek pipeline assets.
Chosunbiz · +4 outlets
Legend Biotech clears FDA hurdle with LB2501 IND approval
The IND clearance advances a new candidate into clinical development for Legend.
Simply Wall Street
UCB wins FDA approval for ZILBRYSQ autoinjector ahead of 2027 launch
The autoinjector approval expands delivery options for UCB's myasthenia gravis therapy.
Mugglehead Investment Magazine
Viatris wins FDA approval for RYZUMVI
The approval adds to Viatris's specialty portfolio amid questions about valuation.
Simply Wall Street · +10 outlets
Quest Diagnostics, Compass and Sellas among biotech stocks in Goldman Sachs $75M basket
Goldman built positions across CAPR, SLS and IBRX, and resumed coverage of Arrowhead with a $74 target, citing looming catalysts.
Stocktwits
Sellas Life Sciences draws retail buzz as traders eye REGAL Phase 3 leukemia catalyst
Investor attention builds ahead of leukemia trial data readout for the small biotech.
Stocktwits